LIVMARLI® (maralixibat) oral solution has been approved by the European Commission for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older and for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients three months of age and older.
Outside of the U.S., European Union and Canada, access to LIVMARLI in certain countries is available through our expanded access program.
Important Safety Information
The most frequently occurring adverse reactions in those who were treated with LIVMARLI in clinical trials was diarrhoea and abdominal pain. None of the adverse reactions were considered serious.
